CASEY PROUGH: Open Payments
NPI 1396723706 · LEES SUMMIT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$109,229 in 286 payments from 20 companies in 2025. Trend: 2023 $110,607 · 2024 $119,392 · 2025 $109,229
Speaker / faculty: $97,525Food & beverage: $4,755Consulting: $3,520Travel & lodging: $3,429
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 97 | $55,340 |
| ABBVIE INC. | 69 | $38,114 |
| Otsuka America Pharmaceutical, Inc. | 20 | $9,328 |
| E.R. Squibb & Sons, L.L.C. | 12 | $4,435 |
| Neurocrine BioSciences, Inc. | 16 | $332 |
| Janssen Pharmaceuticals, Inc | 12 | $299 |
| Vanda Pharmaceuticals Inc. | 10 | $286 |
| Alkermes, Inc. | 9 | $243 |
| Teva Pharmaceuticals USA, Inc. | 12 | $221 |
| Corium, LLC | 5 | $132 |
Products named: CAPLYTA, VRAYLAR, REXULTI, COBENFY, INGREZZA, SPRAVATO, ARISTADA, FANAPT.
Industry payments across MO — which companies pay providers there.
